Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback